Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Investors put $93mm into Paratek as part of merger with Transcept

Executive Summary

As part of its reverse merger with public neuroscience firm Transcept Pharmaceuticals Inc., infectious disease-focused Paratek Pharmaceuticals Inc. will receive $93mm from its current stockholders Omega Funds, HBM Healthcare Investments, and Aisling Capital; Transcept shareholders InterWest Ventures and Roumell Asset Management; and new backers The Baupost Group, Abingworth, and other institutional investors. Post-acquisition, Paratek will focus on lead compound omadacycline, a Phase III-ready oral and intravenous antibiotic.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies